Provided by Tiger Trade Technology Pte. Ltd.

Global Partners LP

50.41
+0.03000.06%
Post-market: 50.410.00000.00%16:04 EDT
Volume:68.12K
Turnover:3.42M
Market Cap:1.71B
PE:10.32
High:50.50
Open:50.02
Low:49.72
Close:50.38
52wk High:53.25
52wk Low:39.58
Shares:34.00M
Float Shares:27.67M
Volume Ratio:1.10
T/O Rate:0.25%
Dividend:3.06
Dividend Rate:6.06%
EPS(TTM):4.89
EPS(LYR):2.11
ROE:27.21%
ROA:5.25%
PB:2.55
PE(LYR):23.89

Loading ...

Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

TIPRANKS
·
Apr 15

Study flags unreported GLP-1 side effects in analysis of social media posts

Bloomberg
·
Apr 14

Strategic Merger in CRO Sector: Baijun Biotech and Hugang Zhongke Sign Integration Agreement

Deep News
·
Apr 14

Morgan Stanley Sticks to Their Buy Rating for GLP J-REIT (3281)

TIPRANKS
·
Apr 14

Press Release: Global Partners Announces Cash Distribution on Series B Preferred Units

Dow Jones
·
Apr 13

NorthStrive Biosciences Announces U.S. Arrival of EL-32 Working Cell Bank and Initiation of Manufacturing Optimization for Dual Myostatin Assets Targeting Muscle Preservation with GLP-1 Therapies in Collaboration with Modulant Biosciences

GlobeNewswire
·
Apr 13

GLP J-REIT Posts Lower Profit After Asset Sales but Keeps Payouts Steady

TIPRANKS
·
Apr 13

GLP J-REIT Outlines Fiscal 2026 Outlook and Growth Strategy

TIPRANKS
·
Apr 13

GLP-1 Genetics Could Inform Treatment, Supporting Future Precision Medicine Approaches

Deep News
·
Apr 09

Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial

TIPRANKS
·
Apr 09

We Picked Amgen Stock a Year Ago. Stick With the Emerging GLP-1 Play. -- Barrons.com

Dow Jones
·
Apr 09

Oral GLP-1 Medications Expand Obesity Treatment Market, Attracting Patients Averse to Injections

Deep News
·
Apr 07

ASCLETIS-B Advances Clinical Development of Fixed-Dose Combination ASC30_39 for Obesity Treatment

Stock News
·
Apr 07

PegBio's CR059 Selection for ADA Late-Breaking Abstract Highlights Monthly-Dosing GLP-1 Potential

Stock News
·
Apr 07

Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

prnewswire
·
Apr 07

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

GlobeNewswire
·
Apr 07

'Hair Loss With GLP-1s Is Real,' Ulta CEO Says As Weight Loss Drug Trend Boosts Hair, Skincare Sales

Benzinga_recent_news
·
Apr 07

Medpace Holdings (MEDP) Is Up 7.8% After GLP-1 Trials Drive 32% Revenue Jump – What’s Changed

Simply Wall St.
·
Apr 07

How Investors May Respond To WEX (WEX) GLP‑1 HRA Launch And Impactive Proxy Challenge

Simply Wall St.
·
Apr 06

Trump’s Medicare GLP-1 drug plan to cost insurers ‘billions,’ Bloomberg reports

TIPRANKS
·
Apr 02